These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23994910)

  • 1. Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
    Kim HS; Shin SJ; Kim JH; Kim H; Choi HJ
    Tohoku J Exp Med; 2013 Sep; 231(1):21-8. PubMed ID: 23994910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Overman MJ; Varadhachary GR; Kopetz S; Adinin R; Lin E; Morris JS; Eng C; Abbruzzese JL; Wolff RA
    J Clin Oncol; 2009 Jun; 27(16):2598-603. PubMed ID: 19164203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study.
    Gulhati P; Raghav K; Shroff RT; Varadhachary GR; Kopetz S; Javle M; Qiao W; Wang H; Morris J; Wolff RA; Overman MJ
    Cancer; 2017 May; 123(6):1011-1017. PubMed ID: 27859010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
    Kim ST; Lee J; Lee KT; Lee JK; Lee KH; Choi SH; Heo JS; Choi DW; Park SH; Park JO; Lim HY; Park YS; Kang WK
    Med Oncol; 2010 Dec; 27(4):1149-54. PubMed ID: 19898973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
    Shoji H; Morizane C; Hiraoka N; Kondo S; Ueno H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
    Jpn J Clin Oncol; 2014 Apr; 44(4):324-30. PubMed ID: 24482413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
    Wang Y; Zhuang RY; Yu YY; Yu S; Hou J; Ji Y; Sun YH; Shen KT; Shen ZB; Liu FL; Zhao NQ; Liu TS
    Oncotarget; 2016 Nov; 7(46):76298-76307. PubMed ID: 27602586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
    Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
    Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
    Gurzu S; Jung I; Comsulea M; Kadar Z; Azamfirei L; Molnar C
    Diagn Pathol; 2013 Sep; 8():150. PubMed ID: 24041405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
    Pilancı KN; Saglam S; Okyar A; Yucel S; Pala-Kara Z; Ordu C; Namal E; Ciftci R; Iner-Koksal U; Kaytan-Saglam E
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):143-50. PubMed ID: 27270460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    Ecker BL; Vollmer CM; Behrman SW; Allegrini V; Aversa J; Ball CG; Barrows CE; Berger AC; Cagigas MN; Christein JD; Dixon E; Fisher WE; Freedman-Weiss M; Guzman-Pruneda F; Hollis RH; House MG; Kent TS; Kowalsky SJ; Malleo G; Salem RR; Salvia R; Schmidt CR; Seykora TF; Zheng R; Zureikat AH; Dickson PV
    JAMA Surg; 2019 Aug; 154(8):706-714. PubMed ID: 31141112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
    Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Cassidy J; Tabernero J; Twelves C; Brunet R; Butts C; Conroy T; Debraud F; Figer A; Grossmann J; Sawada N; Schöffski P; Sobrero A; Van Cutsem E; Díaz-Rubio E
    J Clin Oncol; 2004 Jun; 22(11):2084-91. PubMed ID: 15169795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the ampulla of Vater: what treatment options are available?
    Senatore FJ; Ynson ML; Dasanu CA
    J Oncol Pharm Pract; 2015 Oct; 21(5):364-9. PubMed ID: 24906539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
    Jin Z; Hartgers ML; Sanhueza CT; Shubert CR; Alberts SR; Truty MJ; Muppa P; Nagorney DM; Smyrk TC; Hassan M; Mahipal A
    Eur J Surg Oncol; 2018 May; 44(5):677-683. PubMed ID: 29506768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer.
    Luo HY; Xu RH; Wang F; Qiu MZ; Li YH; Li FH; Zhou ZW; Chen XQ
    Chemotherapy; 2010; 56(2):94-100. PubMed ID: 20357440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
    Nichols RC; George TJ; Zaiden RA; Awad ZT; Asbun HJ; Huh S; Ho MW; Mendenhall NP; Morris CG; Hoppe BS
    Acta Oncol; 2013 Apr; 52(3):498-505. PubMed ID: 23477361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.